A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and bipartisan health care challenges. The blog highlights how the 340B program helps keep drug prices lower than they otherwise would be for all stakeholders; helps lower national expenditures on health care services; and helps protect the safety net for Americans.

“The 340B program was created over 30 years ago with strong bipartisan congressional support and it ought to be preserved in the same manner,” the blog states. “We urge Congress to not allow the self-interested needs of the pharmaceutical industry to supplant the needs of patients and communities across this country who rely on the 340B program for access to affordable, high-quality health care every day.”

Headline
 The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect…
Headline
The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on its request for information on…
Headline
The U.S. District Court for the District of Hawaii Feb. 23 denied a preliminary injunction requested by AstraZeneca in a case challenging the state’s law…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Feb. 19 urged the Health Resources and Services Administration to extend the…
Headline
The Minnesota Court of Appeals Feb. 17 affirmed a lower court decision in ruling that the state’s 340B contract pharmacy law is not preempted by federal law.…
Headline
The Department of Health and Human Services Feb. 13 issued a request for information on a new 340B rebate model program. The RFI said HHS’ Health Resources and…